Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis.

Briot K, Cortet B, Thomas T, Audran M, Blain H, Breuil V, Chapuis L, Chapurlat R, Fardellone P, Feron JM, Gauvain JB, Guggenbuhl P, Kolta S, Lespessailles E, Letombe B, Marcelli C, Orcel P, Seret P, Trémollières F, Roux C.

Joint Bone Spine. 2012 May;79(3):304-13. doi: 10.1016/j.jbspin.2012.02.014. Epub 2012 Apr 19.

PMID:
22521109
2.

Comments about the severe fracture concept used in the 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis, by Briot et al.

Pouilles JM.

Joint Bone Spine. 2012 Oct;79(5):527-8; author reply 528-9. doi: 10.1016/j.jbspin.2012.07.004. Epub 2012 Oct 5. No abstract available.

PMID:
23041470
4.
5.
6.

Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.

[No authors listed]

Menopause. 2010 Jan-Feb;17(1):25-54; quiz 55-6. doi: 10.1097/gme.0b013e3181c617e6.

PMID:
20061894
7.

Characterisation of patients with postmenopausal osteoporosis in French primary healthcare.

Blotman F, Cortet B, Hilliquin P, Avouac B, Allaert FA, Pouchain D, Gaudin AF, Cotté FE, El Hasnaoui A.

Drugs Aging. 2007;24(7):603-14.

PMID:
17658910
8.

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

Iwamoto J, Takeda T, Sato Y.

Curr Med Res Opin. 2006 May;22(5):919-28. Review.

PMID:
16709313
9.

Fracture risk in early postmenopausal women assessed using FRAX.

Trémollieres F, Cochet T, Cohade C, Pouillès JM, Ribot C.

Joint Bone Spine. 2010 Jul;77(4):345-8. doi: 10.1016/j.jbspin.2010.04.012. Epub 2010 Jun 4.

PMID:
20605507
10.

Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.

Reginster JY.

Drugs. 2011 Jan 1;71(1):65-78. doi: 10.2165/11587570-000000000-00000. Review.

11.

Efficiency of bone density testing by dual-biphotonic X-rays absorptiometry for diagnosis of osteoporosis according to French guideline recommendations: the PRESAGE study.

Guggenbuhl P, Dufour R, Liu-Léage S, Sapin H, Cortet B.

Joint Bone Spine. 2011 Oct;78(5):493-8. doi: 10.1016/j.jbspin.2010.12.009. Epub 2011 Mar 2.

PMID:
21367636
13.

Strategies for treatment to prevent fragility fractures in postmenopausal women.

Geusens P.

Best Pract Res Clin Rheumatol. 2009 Dec;23(6):727-40. doi: 10.1016/j.berh.2009.09.001. Review.

PMID:
19945685
14.

Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.

Rossini M, Viapiana O, Gatti D, Adami S.

Clin Ther. 2009 Jul;31(7):1497-510. doi: 10.1016/j.clinthera.2009.07.018. Review.

PMID:
19695399
15.

Preventing osteoporosis-related fractures: an overview.

Gass M, Dawson-Hughes B.

Am J Med. 2006 Apr;119(4 Suppl 1):S3-S11. Review.

PMID:
16563939
16.

2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis.

Briot K, Cortet B, Roux C, Fardet L, Abitbol V, Bacchetta J, Buchon D, Debiais F, Guggenbuhl P, Laroche M, Legrand E, Lespessailles E, Marcelli C, Weryha G, Thomas T; Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO).

Joint Bone Spine. 2014 Dec;81(6):493-501.

PMID:
25455041
17.

Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society.

North American Menopause Society.

Menopause. 2006 May-Jun;13(3):340-67; quiz 368-9.

PMID:
16735931
18.

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A; National Osteoporosis Guideline Group.

Osteoporos Int. 2008 Oct;19(10):1395-408. doi: 10.1007/s00198-008-0712-1. Epub 2008 Aug 28. Erratum in: Osteoporos Int. 2009 Mar;20(3):499-502.

PMID:
18751937
19.

Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(20):1-180. Epub 2006 Nov 1.

20.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial.

N Engl J Med. 2007 May 3;356(18):1809-22.

Supplemental Content

Support Center